An observational study in Pediatric Solid Tumors, Rhabdomyosarcoma and Sarcoma, sponsored by University of Rochester. Not yet recruiting at 1 site in United States. Open to participants aged 1 Month to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by University of Rochester · Observational
Among 179 studies in Rhabdomyosarcoma with a site in United States — 30 open to participants now, 56 under way, 3 of them phase 3. Rhabdomyosarcoma · United States.
Among the 179 studies in Rhabdomyosarcoma with a site in United States, this one is the 12th largest by planned enrollment of the 14 observational ones that give a count, is one of 8 that started in 2026, is one of 14 observational ones, reaches primary completion later than 41 of the 55 other live ones, and was the 172nd registered.
238 studies on the registry are indexed under Rhabdomyosarcoma; 49 are open to participants now.
Browse Rhabdomyosarcoma studies →30 of the 179 studies in Rhabdomyosarcoma with a site in United States are open now. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Children's Oncology Group · Sites in United States, Canada
University of California, Irvine · Sites in United States
University of Florida · Sites in United States
Children's National Research Institute · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Rhabdomyosarcoma studies recruiting now, 8 (21%) set no upper age limit and 31 (79%) stop at 75 or younger; 35 take children under 18; 0 take healthy volunteers.
This study: 1 Month to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
179 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 84 · Phase 2 88 · Phase 3 8
First in 1993; this study’s year is marked. 8 started in 2026.
This study's planned enrollment of 10 is below the median of 77 across 21 observational studies indexed under Rhabdomyosarcoma.
Median enrollment 30 across the 161 interventional studies, 125 across the 14 observational. Of the 114 that completed or were terminated, 54 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 179 have an industry lead sponsor. The 10 most frequent:
University of Rochester is the lead sponsor of 729 studies on the registry; 116 are open to participants now.
Of its 56 completed or terminated interventional studies of FDA-regulated products, 44 (79%) have results posted.
University of Rochester has 1 study filed under Rhabdomyosarcoma — fewer than ten, so there is no comparison to draw.
15 of the studies in Rhabdomyosarcoma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04337177Valent Technologies, LLCFlavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | 2026-12 |
| NCT01871766St. Jude Children's Research HospitalRisk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy | 2026-12 |
| NCT02508038University of Wisconsin, MadisonAlpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | 2026-12 |
| NCT02013336South Plains Oncology ConsortiumPhase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | 2026-12 |
| NCT04299113Jonsson Comprehensive Cancer CenterMocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma | 2026-12-30 |
Among the 179 studies in Rhabdomyosarcoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the feasibility and safety of ICG-guided intraoperative lymphography for detecting sentinel lymph nodes (SLN) in pediatric patients with solid tumors who require retroperitoneal lymph node dissection/sampling.
This trial is a single-site cross-sectional study. The injection of ICG directly into lymphatics draining the primary tumor will take place at the time of operation after the patient is under anesthesia.
Pediatric patients aged 1 month to 17 years with diagnosed solid tumors who are receiving care at the University of Rochester Medical Center (URMC), Department of Surgery. Eligible participants are those scheduled to undergo lymph node sampling as part of standard clinical management. Participants will be identified through pediatric oncology, pediatric surgery, and tumor board evaluations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: ICG (Indocyanine Green)
Lymphatic mapping
Percentage of Patients with Successful Sentinel Lymph Node (SLN) Detection Using ICG Fluorescence
Success is defined as the intraoperative identification of at least one fluorescent sentinel lymph node (SLN) after indocyanine green (ICG) injection using an Iridium system optimized for near-infrared detection. Visualization of the SLN indicates uptake of ICG within the lymphatic basin.
Time frame: Baseline
Accuracy of SLN Biopsy as Measured by Concordance Between SLN Pathology and Nodal Basin Pathology
Accuracy is assessed by comparing the pathology results of the SLN and the retroperitoneal lymph node basin dissection. True positives and true negatives are defined as SLN and nodal basin showing matching tumor status (both positive or both negative). Discordant finding is defined as tumor basin positive for tumor while SLN is negative for tumor. Discordant findings are considered false negatives. A tumor positive SLN in a tumor negative nodal basin is not considered discordant or false positive because sentinel may be the first and only tumor involved lymph node within the nodal basin.
Time frame: During surgery (Day 0), based on intraoperative and postoperative pathology reports finalized within 7 days
Start is estimated for Dec 2026; primary completion for Jul 2028, 19 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.